gamma-aminobutyric acid has been researched along with Intellectual Disability in 51 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 9.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 9.08 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "The short- and long-term clinical efficacy of add-on vigabatrin treatment was evaluated in a group of 36 patients with intellectual disability and drug-refractory epilepsy." | 9.08 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "In a retrospective evaluation of 32 inpatients with therapy-resistant epilepsy and intellectual disability, the efficacy of pregabalin (PGB) treatment was assessed after 6 and 12 months." | 7.74 | Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability. ( Bocchicchio, M; Feuerbaum, E; Huber, B; May, T; Meinert, T; Robertson, E; Schorlemmer, H; Seidel, M; Wagner, W; Wilking, E, 2008) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 7.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "To assess the role of glutamate as an excitatory neurotransmitter and neurotoxin in pyridoxine-dependent epilepsy." | 7.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "The results indicate that control of epilepsy might not suffice as the therapeutic aim in treating of pyridoxine dependency." | 7.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 7.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Pyridoxine-dependent epilepsy is a rare autosomal recessive disorder." | 7.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "After 3 months, 42% of the patients with intellectual disability had experienced a reduction in seizure frequency of more than 50% (responders)." | 6.69 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 6.69 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| " In view of the evidence for the role of excitatory amino acids in destruction of CNS nerve cells, the optimal treatment must counteract the raised levels of CSF glutamate and the dosage of vitamin B6 must be adjusted accordingly." | 5.29 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 5.29 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "The development of mental retardation might theoretically be prevented by adjusting the dose of vitamin B6 to achieve not only remission of epilepsy but also normalization of CSF glutamate." | 5.29 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 5.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "Ten patients with refractory partial epilepsy, previous mental retardation and psychosis or other significant psychiatric morbidity treated with vigabatrin were submitted periodically to specific tests (to quantify any possible change in behavioural parameters) and also to EEG recordings." | 5.09 | Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. ( Baldi, PL; De Agostini, G; Ferrari Ginevra, O; Lanzi, G; Muzio, C; Termine, C; Veggiotti, P, 1999) |
| "The short- and long-term clinical efficacy of add-on vigabatrin treatment was evaluated in a group of 36 patients with intellectual disability and drug-refractory epilepsy." | 5.08 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 5.08 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "In a retrospective evaluation of 32 inpatients with therapy-resistant epilepsy and intellectual disability, the efficacy of pregabalin (PGB) treatment was assessed after 6 and 12 months." | 3.74 | Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability. ( Bocchicchio, M; Feuerbaum, E; Huber, B; May, T; Meinert, T; Robertson, E; Schorlemmer, H; Seidel, M; Wagner, W; Wilking, E, 2008) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 3.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 3.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "To evaluate the relationship of gabapentin therapy with choreoathetotic movements in mentally retarded patients treated with intractable epilepsy." | 3.69 | Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. ( Chudnow, RS; Dewey, RB; Lawson, CR, 1997) |
| "We suggest that, in patients with mental retardation and epilepsy, involuntary movements may either occur as reversible side effects of gabapentin therapy or result from a previously undescribed adverse drug interaction with other antiepileptic agents." | 3.69 | Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. ( Chudnow, RS; Dewey, RB; Lawson, CR, 1997) |
| "The results indicate that control of epilepsy might not suffice as the therapeutic aim in treating of pyridoxine dependency." | 3.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "To assess the role of glutamate as an excitatory neurotransmitter and neurotoxin in pyridoxine-dependent epilepsy." | 3.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "Pyridoxine-dependent epilepsy is a rare autosomal recessive disorder." | 3.69 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| "The content of free amino acids and the dipeptide homocarnosine was examined in the cerebrospinal fluid of children with post-meningitis hydrocephalus." | 3.66 | [Concentration of free amino acids and homocarnosine dipeptide in the cerebrospinal fluid of children with hydrocephalus]. ( Bondarenko, TI; Makletsova, MG; Sukhomovskiĭ, BI, 1983) |
| "After 3 months, 42% of the patients with intellectual disability had experienced a reduction in seizure frequency of more than 50% (responders)." | 2.69 | Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability. ( Ylinen, A, 1998) |
| "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26." | 2.69 | Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. ( Choueri, R; Helmers, S; Holmes, G; Khurana, DS; Mikati, MA; Riviello, J, 1998) |
| "Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped." | 2.39 | The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. ( Mattson, RH, 1996) |
| "Medical history interviews, seizure surveys, Vineland Adaptive Behavior Scales Second Edition and other behavioural surveys were completed by primary care givers of 28 participants in Simons Searchlight." | 1.72 | Neurodevelopmental phenotypes associated with pathogenic variants in ( Brooks, E; Chung, W; Geltzeiler, A; Green Snyder, L; Kahen, A; Kavus, H; Kentros, C; Taylor, C, 2022) |
| "elegans allows our electroconvulsive seizure (ES) assay to be used as a behavioral readout of the locomotor circuit and neuronal function." | 1.62 | O-GlcNAc transferase OGT-1 and the ubiquitin ligase EEL-1 modulate seizure susceptibility in C. elegans. ( Dawson-Scully, K; Giles, A; Grill, B; Opperman, KJ; Suthakaran, N; Wiggins, J, 2021) |
| "Gamma-aminobutyric acid (GABA) is a major modulator in brain maturation and its role in many different neurodevelopmental disorders has been widely reported." | 1.48 | Gamma-aminobutyric acid levels in cerebrospinal fluid in neuropaediatric disorders. ( Armstrong-Morón, J; Artuch, R; Casado, M; Cortès-Saladelafont, E; Cuadras, D; García-Cazorla, À; Molero-Luis, M; Montoya, J; Yubero, D, 2018) |
| "West syndrome is the triad of infantile spasms, interictal hypsarrhythmia, and mental retardation." | 1.46 | Rapid whole-genome sequencing identifies a novel ( Batalov, S; Chowdhury, S; Dimmock, DM; Farnaes, L; Kingsmore, SF; Nahas, SA; Nelson, J, 2017) |
| "Clinical findings include mild-moderate mental retardation, disproportionate language dysfunction, hypotonia, hyporeflexia, autistic behaviors, seizures, and hallucinations." | 1.32 | Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. ( Acosta, MT; Berry, GT; Conry, JA; Gibson, KM; Gropman, A; Novotny, EJ; Pearl, PL; Rogawski, MA; Theodore, WH; Tuchman, M; Vezina, LG, 2003) |
| "The Fragile X syndrome, a common form of mental retardation in humans, is caused by silencing the fragile X mental retardation (FMR1) gene leading to the absence of the encoded fragile X mental retardation protein 1 (FMRP)." | 1.31 | Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome. ( Braun, K; Gruss, M, 2001) |
| "Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "We suggest that, in patients with mental retardation and epilepsy, involuntary movements may either occur as reversible side effects of gabapentin therapy or result from a previously undescribed adverse drug interaction with other antiepileptic agents." | 1.30 | Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. ( Chudnow, RS; Dewey, RB; Lawson, CR, 1997) |
| "One patient developed recurrent choreiform movements after drug rechallenge." | 1.30 | Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. ( Chudnow, RS; Dewey, RB; Lawson, CR, 1997) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 1.29 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "The development of mental retardation might theoretically be prevented by adjusting the dose of vitamin B6 to achieve not only remission of epilepsy but also normalization of CSF glutamate." | 1.29 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| " In view of the evidence for the role of excitatory amino acids in destruction of CNS nerve cells, the optimal treatment must counteract the raised levels of CSF glutamate and the dosage of vitamin B6 must be adjusted accordingly." | 1.29 | Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. ( Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (19.61) | 18.7374 |
| 1990's | 13 (25.49) | 18.2507 |
| 2000's | 14 (27.45) | 29.6817 |
| 2010's | 9 (17.65) | 24.3611 |
| 2020's | 5 (9.80) | 2.80 |
| Authors | Studies |
|---|---|
| Suthakaran, N | 1 |
| Wiggins, J | 1 |
| Giles, A | 1 |
| Opperman, KJ | 1 |
| Grill, B | 1 |
| Dawson-Scully, K | 1 |
| Goeldner, C | 1 |
| Kishnani, PS | 1 |
| Skotko, BG | 1 |
| Casero, JL | 1 |
| Hipp, JF | 1 |
| Derks, M | 1 |
| Hernandez, MC | 1 |
| Khwaja, O | 1 |
| Lennon-Chrimes, S | 1 |
| Noeldeke, J | 1 |
| Pellicer, S | 1 |
| Squassante, L | 1 |
| Visootsak, J | 1 |
| Wandel, C | 1 |
| Fontoura, P | 1 |
| d'Ardhuy, XL | 1 |
| Hines, DJ | 1 |
| Contreras, A | 1 |
| Garcia, B | 1 |
| Barker, JS | 1 |
| Boren, AJ | 1 |
| Moufawad El Achkar, C | 1 |
| Moss, SJ | 1 |
| Hines, RM | 1 |
| Cediel, ML | 1 |
| Stawarski, M | 1 |
| Blanc, X | 1 |
| Nosková, L | 1 |
| Magner, M | 1 |
| Platzer, K | 1 |
| Gburek-Augustat, J | 1 |
| Baldridge, D | 1 |
| Constantino, JN | 1 |
| Ranza, E | 1 |
| Bettler, B | 1 |
| Antonarakis, SE | 1 |
| Kahen, A | 1 |
| Kavus, H | 1 |
| Geltzeiler, A | 1 |
| Kentros, C | 1 |
| Taylor, C | 1 |
| Brooks, E | 1 |
| Green Snyder, L | 1 |
| Chung, W | 1 |
| Farnaes, L | 1 |
| Nahas, SA | 1 |
| Chowdhury, S | 1 |
| Nelson, J | 1 |
| Batalov, S | 1 |
| Dimmock, DM | 1 |
| Kingsmore, SF | 1 |
| Niturad, CE | 1 |
| Lev, D | 1 |
| Kalscheuer, VM | 1 |
| Charzewska, A | 1 |
| Schubert, J | 1 |
| Lerman-Sagie, T | 1 |
| Kroes, HY | 1 |
| Oegema, R | 1 |
| Traverso, M | 1 |
| Specchio, N | 1 |
| Lassota, M | 1 |
| Chelly, J | 1 |
| Bennett-Back, O | 1 |
| Carmi, N | 1 |
| Koffler-Brill, T | 1 |
| Iacomino, M | 1 |
| Trivisano, M | 1 |
| Capovilla, G | 1 |
| Striano, P | 1 |
| Nawara, M | 1 |
| Rzonca, S | 1 |
| Fischer, U | 1 |
| Bienek, M | 1 |
| Jensen, C | 1 |
| Hu, H | 1 |
| Thiele, H | 1 |
| Altmüller, J | 1 |
| Krause, R | 1 |
| May, P | 1 |
| Becker, F | 1 |
| Balling, R | 1 |
| Biskup, S | 1 |
| Haas, SA | 1 |
| Nürnberg, P | 1 |
| van Gassen, KLI | 1 |
| Lerche, H | 1 |
| Zara, F | 1 |
| Maljevic, S | 1 |
| Leshinsky-Silver, E | 1 |
| Jung, EM | 1 |
| Moffat, JJ | 1 |
| Liu, J | 1 |
| Dravid, SM | 1 |
| Gurumurthy, CB | 1 |
| Kim, WY | 1 |
| Cortès-Saladelafont, E | 1 |
| Molero-Luis, M | 1 |
| Cuadras, D | 1 |
| Casado, M | 1 |
| Armstrong-Morón, J | 1 |
| Yubero, D | 1 |
| Montoya, J | 1 |
| Artuch, R | 1 |
| García-Cazorla, À | 1 |
| Hernandez, CC | 1 |
| XiangWei, W | 1 |
| Hu, N | 1 |
| Shen, D | 1 |
| Shen, W | 1 |
| Lagrange, AH | 1 |
| Zhang, Y | 1 |
| Dai, L | 1 |
| Ding, C | 1 |
| Sun, Z | 1 |
| Hu, J | 1 |
| Zhu, H | 1 |
| Jiang, Y | 1 |
| Macdonald, RL | 1 |
| Bonnet-Brilhault, F | 1 |
| Alirol, S | 1 |
| Blanc, R | 1 |
| Bazaud, S | 1 |
| Marouillat, S | 1 |
| Thépault, RA | 1 |
| Andres, CR | 1 |
| Lemonnier, É | 1 |
| Barthélémy, C | 1 |
| Raynaud, M | 1 |
| Toutain, A | 1 |
| Gomot, M | 1 |
| Laumonnier, F | 1 |
| McQuire, C | 1 |
| Hassiotis, A | 1 |
| Harrison, B | 1 |
| Pilling, S | 1 |
| Huber, B | 1 |
| Bocchicchio, M | 1 |
| Feuerbaum, E | 1 |
| May, T | 1 |
| Meinert, T | 1 |
| Robertson, E | 1 |
| Schorlemmer, H | 1 |
| Wagner, W | 1 |
| Wilking, E | 1 |
| Seidel, M | 1 |
| Modur, PN | 1 |
| Milteer, WE | 1 |
| Knerr, I | 1 |
| Gibson, KM | 4 |
| Jakobs, C | 3 |
| Pearl, PL | 3 |
| Carpay, JA | 1 |
| Aalbers, K | 1 |
| Graveland, GA | 1 |
| Engelsman, M | 1 |
| Lucey, BP | 1 |
| Noetzel, MJ | 1 |
| Duntley, SP | 1 |
| Edvardson, S | 1 |
| Baumann, AM | 1 |
| Mühlenhoff, M | 1 |
| Stephan, O | 1 |
| Kuss, AW | 1 |
| Shaag, A | 1 |
| He, L | 1 |
| Zenvirt, S | 1 |
| Tanzi, R | 1 |
| Gerardy-Schahn, R | 1 |
| Elpeleg, O | 1 |
| Acosta, MT | 1 |
| Vezina, LG | 2 |
| Theodore, WH | 1 |
| Rogawski, MA | 1 |
| Novotny, EJ | 1 |
| Gropman, A | 1 |
| Conry, JA | 1 |
| Berry, GT | 1 |
| Tuchman, M | 2 |
| SHIMIZU, S | 1 |
| BERTAMINO, F | 1 |
| VENTO, R | 1 |
| Gupta, M | 1 |
| Snead, OC | 1 |
| Smit, LM | 1 |
| Di Lazzaro, V | 1 |
| Oliviero, A | 1 |
| Tonali, PA | 1 |
| Felicetti, L | 1 |
| De Marco, MB | 1 |
| Saturno, E | 1 |
| Pilato, F | 1 |
| Pescatori, M | 1 |
| Dileone, M | 1 |
| Pasqualetti, P | 1 |
| Ricci, E | 1 |
| Alkan, A | 1 |
| Kutlu, R | 1 |
| Aslan, M | 1 |
| Sigirci, A | 1 |
| Orkan, I | 1 |
| Yakinci, C | 1 |
| Leuzzi, V | 1 |
| Di Sabato, ML | 1 |
| Deodato, F | 1 |
| Rizzo, C | 1 |
| Boenzi, S | 1 |
| Carducci, C | 1 |
| Malaspina, P | 1 |
| Liberanome, C | 1 |
| Dionisi-Vici, C | 1 |
| Bondarenko, TI | 1 |
| Makletsova, MG | 1 |
| Sukhomovskiĭ, BI | 1 |
| Semenov, SF | 1 |
| Sazonova, NS | 2 |
| Kogan, RD | 1 |
| Sugimoto, T | 1 |
| Yasuhara, A | 1 |
| Nishida, N | 1 |
| Sakane, Y | 1 |
| Sugimoto, Y | 1 |
| Avrutskaia, IG | 1 |
| Ermolina, LA | 1 |
| Baumeister, FA | 1 |
| Gsell, W | 1 |
| Shin, YS | 1 |
| Egger, J | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Vossler, DG | 1 |
| Mattson, RH | 1 |
| Christensen, E | 1 |
| Fowler, B | 1 |
| Clarke, MA | 1 |
| Hammersen, G | 1 |
| Raab, K | 1 |
| Kobori, J | 1 |
| Moosa, A | 1 |
| Vollmer, B | 1 |
| Rossier, E | 1 |
| Iafolla, AK | 1 |
| Matern, D | 1 |
| Brouwer, OF | 1 |
| Finkelstein, J | 1 |
| Aksu, F | 1 |
| Weber, HP | 1 |
| Bakkeren, JA | 1 |
| Gabreels, FJ | 1 |
| Bluestone, D | 1 |
| Barron, TF | 1 |
| Beauvais, P | 1 |
| Rabier, D | 1 |
| Santos, C | 1 |
| Lehnert, W | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Chudnow, RS | 1 |
| Dewey, RB | 1 |
| Lawson, CR | 1 |
| Ylinen, A | 1 |
| Mikati, MA | 1 |
| Choueri, R | 1 |
| Khurana, DS | 1 |
| Riviello, J | 1 |
| Helmers, S | 1 |
| Holmes, G | 1 |
| Veggiotti, P | 1 |
| De Agostini, G | 1 |
| Muzio, C | 1 |
| Termine, C | 1 |
| Baldi, PL | 1 |
| Ferrari Ginevra, O | 1 |
| Lanzi, G | 1 |
| Roubergue, A | 1 |
| Schlumberger, ME | 1 |
| Billette de Villemeur, T | 1 |
| Burd, L | 1 |
| Stenehjem, A | 1 |
| Franceschini, LA | 1 |
| Kerbeshian, J | 1 |
| Carta, MG | 1 |
| Hardoy, MC | 1 |
| Dessì, I | 1 |
| Hardoy, MJ | 1 |
| Carpiniello, B | 1 |
| Bozikas, V | 1 |
| Bascialla, F | 1 |
| Yulis, P | 1 |
| Savvidou, I | 1 |
| Karavatos, A | 1 |
| Crawford, P | 1 |
| Brown, S | 1 |
| Kerr, M | 1 |
| Gruss, M | 1 |
| Braun, K | 1 |
| Matsushita, K | 1 |
| Gjessing, LR | 1 |
| Mattes, JA | 1 |
| Sasaki, T | 1 |
| Minagawa, M | 1 |
| Yamamoto, T | 1 |
| Ichihashi, H | 1 |
| Yamaguchi, S | 1 |
| Orii, T | 1 |
| Yasuda, K | 1 |
| Kohno, Y | 1 |
| Balashova, EG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)[NCT02024789] | Phase 2 | 173 participants (Actual) | Interventional | 2014-05-05 | Completed | ||
| Autism and Glutamatergic Synapse : Research of Genetic Mutations and Identification of Clinical and Neurophysiological Markers.[NCT01770548] | 497 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gamma-aminobutyric acid and Intellectual Disability
| Article | Year |
|---|---|
Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.
Topics: Adaptation, Psychological; Adolescent; Anticonvulsants; Antioxidants; Antipsychotic Agents; Child; C | 2015 |
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
Topics: Acetates; Amines; Anticonvulsants; Cerebral Palsy; Cyclohexanecarboxylic Acids; Disabled Persons; Dr | 1996 |
6 trials available for gamma-aminobutyric acid and Intellectual Disability
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA
Topics: Adolescent; Child; Child, Preschool; Down Syndrome; gamma-Aminobutyric Acid; Humans; Intellectual Di | 2022 |
Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Humans; Intell | 2008 |
Antiepileptic efficacy of vigabatrin in people with severe epilepsy and intellectual disability.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Epilepsy; Follow-Up Studies; | 1998 |
Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 1998 |
Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Drug Administratio | 1999 |
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administrati | 2001 |
43 other studies available for gamma-aminobutyric acid and Intellectual Disability
| Article | Year |
|---|---|
O-GlcNAc transferase OGT-1 and the ubiquitin ligase EEL-1 modulate seizure susceptibility in C. elegans.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Susceptibility; GABAergic | 2021 |
Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA
Topics: Animals; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Mice; Mutation; Receptors, GABA-A | 2022 |
GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy.
Topics: Epilepsy; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Intellectual Disability; Nervous System Mal | 2022 |
Neurodevelopmental phenotypes associated with pathogenic variants in
Topics: Autism Spectrum Disorder; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Humans; | 2022 |
Rapid whole-genome sequencing identifies a novel
Topics: Brain; Developmental Disabilities; Electroencephalography; gamma-Aminobutyric Acid; Genome; High-Thr | 2017 |
Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features.
Topics: Adolescent; Adult; Animals; Brain Diseases; Child; Child, Preschool; Cleft Palate; Developmental Dis | 2017 |
Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior.
Topics: Animals; Autism Spectrum Disorder; Avoidance Learning; Behavior, Animal; Cell Count; Cerebral Cortex | 2017 |
Gamma-aminobutyric acid levels in cerebrospinal fluid in neuropaediatric disorders.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Cohort Studies; Epilepsy; Female; gamma-Amin | 2018 |
Altered inhibitory synapses in de novo GABRA5 and GABRA1 mutations associated with early onset epileptic encephalopathies.
Topics: Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Acid; Genetic Predisposition to Diseas | 2019 |
GABA/Glutamate synaptic pathways targeted by integrative genomic and electrophysiological explorations distinguish autism from intellectual disability.
Topics: Acoustic Stimulation; Autistic Disorder; Cell Adhesion Molecules, Neuronal; Child, Preschool; Electr | 2016 |
Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Dose-Response Relations | 2008 |
Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Ataxia; Behavioral Symptoms; Child; Child, | 2008 |
Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Utilization Rev | 2009 |
Paroxysmal arousals and myoclonic movements associated with interictal epileptiform discharges in NREM and REM sleep.
Topics: Adolescent; Amines; Antiparkinson Agents; Arousal; Chromosome Disorders; Chromosome Inversion; Chrom | 2011 |
West syndrome caused by ST3Gal-III deficiency.
Topics: Adolescent; Age of Onset; Animals; Anticonvulsants; beta-Galactoside alpha-2,3-Sialyltransferase; Ch | 2013 |
Clinical spectrum of succinic semialdehyde dehydrogenase deficiency.
Topics: Adolescent; Adult; Aldehyde Oxidoreductases; Autistic Disorder; Child; Child, Preschool; Cohort Stud | 2003 |
[Use of aminobutyric acid (GABA) in congenital oligophrenia and in infantile cerebral paralysis].
Topics: Amino Acids; Aminobutyrates; Antifibrinolytic Agents; Cerebral Palsy; Diet, Reducing; gamma-Aminobut | 1961 |
[GABOB IN PEDIATRICS. CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY OF 28 CASES].
Topics: Adolescent; Aminobutyrates; Barbiturates; Brain Injuries; Cerebral Palsy; Child; Electroencephalogra | 1964 |
Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria).
Topics: Adult; Aldehyde Oxidoreductases; Atrophy; Cerebellum; Chromatography, High Pressure Liquid; Chromato | 2003 |
Changes in motor cortex excitability in facioscapulohumeral muscular dystrophy.
Topics: Adolescent; Adult; Diazepam Binding Inhibitor; Electric Stimulation; Epilepsy; gamma-Aminobutyric Ac | 2004 |
Pyridoxine-dependent seizures: magnetic resonance spectroscopy findings.
Topics: Aspartic Acid; Brain Damage, Chronic; Child; Choline; Consanguinity; Creatine; Diagnosis, Differenti | 2004 |
Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency.
Topics: Adolescent; Brain; Brain Diseases, Metabolic; Dystonic Disorders; Epilepsy; Extremities; GABA Agents | 2007 |
[Concentration of free amino acids and homocarnosine dipeptide in the cerebrospinal fluid of children with hydrocephalus].
Topics: Amino Acids; Carnosine; Cerebral Ventricles; Child, Preschool; Dipeptides; gamma-Aminobutyric Acid; | 1983 |
[Dynamics of immunoglobulin levels and neuroimmune processes in intellectually deficient children].
Topics: Autoantibodies; Brain; Child; Female; gamma-Aminobutyric Acid; Humans; Immunoglobulin A; Immunoglobu | 1983 |
[3 cases of acute encephalopathy associated with calcium hopantenate administration].
Topics: Acute Disease; Child, Preschool; Female; gamma-Aminobutyric Acid; Humans; Infant; Intellectual Disab | 1983 |
[Selective action of metabolic drug therapy in mentally retarded children].
Topics: Child; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Pantothenic Acid; Piracetam; Pyrith | 1980 |
[Use of metabolically active preparations to study mild forms of mental deficiency].
Topics: Child; Diagnosis, Differential; Female; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Ma | 1980 |
Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine.
Topics: Adrenocorticotropic Hormone; Electroencephalography; Epilepsy; gamma-Aminobutyric Acid; Genes, Reces | 1994 |
Gabapentin associated with aggressive behavior in pediatric patients with seizures.
Topics: Acetates; Adolescent; Age Factors; Aggression; Amines; Anticonvulsants; Child; Child Behavior Disord | 1996 |
Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; ga | 1996 |
The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients.
Topics: Adolescent; Adult; Aldehyde Oxidoreductases; Child; Child, Preschool; Developmental Disabilities; Di | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Athetosis; Chorea; Cyclohexanecarboxylic Acids; Epilepsy; | 1997 |
[The usefulness of statistical tests in publications].
Topics: 4-Aminobutyrate Transaminase; Anti-Inflammatory Agents; Anticonvulsants; Chi-Square Distribution; En | 1999 |
A 15-year follow-up of a boy with pyridoxine (vitamin B6)-dependent seizures with autism, breath holding, and severe mental retardation.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Autistic Disorder; Diagnosis, Dif | 2000 |
Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Comorbidity; Cyclohexanecarboxylic Acid | 2001 |
Gabapentin for behavioral dyscontrol with mental retardation.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug Th | 2001 |
Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Alanine; Amino Acids; Animals; Aspartic Acid; Brain; Brain St | 2001 |
Analysis of gamma-amino-beta-hydroxy butyric acid (GABOB) by chromatography and electrophoresis.
Topics: Adult; Amino Acids; Anophthalmos; Autoanalysis; Chromatography, Ion Exchange; Chromatography, Paper; | 1979 |
Valproic acid for nonaffective aggression in the mentally retarded.
Topics: Adult; Affect; Aggression; Animals; Female; gamma-Aminobutyric Acid; Humans; Intellectual Disability | 1992 |
A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.
Topics: Acute Disease; Blood Glucose; Brain Diseases; Carboxylic Acids; Child, Preschool; Female; gamma-Amin | 1991 |
A case of glutaric aciduria type I with unique abnormalities in the cerebral CT findings.
Topics: Baclofen; Female; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Glutarates; Glutary | 1987 |
[Experience with clinical use of the drug gammalon in children with cerebral palsy].
Topics: Adolescent; Aminobutyrates; Cerebral Palsy; Child; Child, Preschool; Electromyography; Feeding and E | 1974 |